Original ArticleStandard-dose Gentamicin (cas 1403-66-3) does not increase risk of patent ductus arteriosus

Add time:09/01/2019    Source:sciencedirect.com

BackgroundRates of patent ductus arteriosus (PDA) and infection are high in preterm infants. Preterm infants with infection are more likely to develop symptomatic PDA, a potentially fatal disease. Clinically, Gentamicin (cas 1403-66-3) is widely used for early-onset infection in neonates including preterm infants. A recent study demonstrated that standard-dose gentamicin itself, not infection, increased risk of PDA in mice, suggesting that gentamicin should be avoided in neonates with a risk of PDA. This claim has been insufficiently investigated in subsequent in-vivo experiments. We reevaluated the in-vivo effect of standard-dose gentamicin on patency of the rat ductus arteriosus (DA).

We also recommend Trading Suppliers and Manufacturers of Gentamicin (cas 1403-66-3). Pls Click Website Link as below: cas 1403-66-3 suppliers

Prev:The isolation of crystalline fradicin (cas 1403-61-8) from fermentation media
Next:Overproduction of Gentamicin (cas 1403-66-3) B in industrial strain Micromonospora echinospora CCTCC M 2018898 by cloning of the missing genes genR and genS)